Dexcom Inc (NASDAQ: DXCM) has a higher price-to-earnings ratio of 82.26x compared to its average ratio, The 36-month beta value for DXCM is at 1.25. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 8 rating it as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for DXCM is 391.29M, and currently, shorts hold a 3.01% of that float. The average trading volume for DXCM on May 09, 2024 was 3.18M shares.
DXCM) stock’s latest price update
Dexcom Inc (NASDAQ: DXCM)’s stock price has decreased by -2.06 compared to its previous closing price of 130.10. However, the company has seen a 1.22% increase in its stock price over the last five trading sessions. Seeking Alpha reported 2024-05-06 that DexCom shares took a slight tumble after earnings were announced Thursday evening off of strong results. Guidance for the year was upgraded due to growing demand and FDA clearance for the Apple Watch as a primary display for blood sugars. Despite concerns over timing and other risks, I believe there will be sustained revenue growth and that there is potential for long-term price accretion.
DXCM’s Market Performance
DXCM’s stock has risen by 1.22% in the past week, with a monthly drop of -9.28% and a quarterly rise of 0.64%. The volatility ratio for the week is 1.95% while the volatility levels for the last 30 days are 3.32% for Dexcom Inc The simple moving average for the last 20 days is -3.67% for DXCM stock, with a simple moving average of 10.94% for the last 200 days.
Analysts’ Opinion of DXCM
Many brokerage firms have already submitted their reports for DXCM stocks, with RBC Capital Mkts repeating the rating for DXCM by listing it as a “Outperform.” The predicted price for DXCM in the upcoming period, according to RBC Capital Mkts is $165 based on the research report published on March 12, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see DXCM reach a price target of $131. The rating they have provided for DXCM stocks is “Equal-Weight” according to the report published on May 30th, 2023.
Raymond James gave a rating of “Strong Buy” to DXCM, setting the target price at $138 in the report published on April 17th of the previous year.
DXCM Trading at -3.62% from the 50-Day Moving Average
After a stumble in the market that brought DXCM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.27% of loss for the given period.
Volatility was left at 3.32%, however, over the last 30 days, the volatility rate increased by 1.95%, as shares sank -9.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.49% upper at present.
During the last 5 trading sessions, DXCM rose by +1.22%, which changed the moving average for the period of 200-days by -0.23% in comparison to the 20-day moving average, which settled at $131.64. In addition, Dexcom Inc saw 2.68% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DXCM starting from Brown Michael Jon, who sale 629 shares at the price of $126.25 back on Apr 30 ’24. After this action, Brown Michael Jon now owns 68,212 shares of Dexcom Inc, valued at $79,411 using the latest closing price.
Dolan Matthew Vincent, the EVP Strategy and Corporate Dev of Dexcom Inc, sale 1,990 shares at $137.81 during a trade that took place back on Apr 15 ’24, which means that Dolan Matthew Vincent is holding 42,377 shares at $274,242 based on the most recent closing price.
Stock Fundamentals for DXCM
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.63 for the gross margin
The net margin for Dexcom Inc stands at 0.17. The total capital return value is set at 0.13. Equity return is now at value 28.54, with 10.66 for asset returns.
Based on Dexcom Inc (DXCM), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at 0.31. The debt to equity ratio resting at 1.15. The interest coverage ratio of the stock is 32.1.
Currently, EBITDA for the company is 916.7 million with net debt to EBITDA at 2.0. When we switch over and look at the enterprise to sales, we see a ratio of 13.79. The receivables turnover for the company is 3.86for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.90.
Conclusion
In conclusion, Dexcom Inc (DXCM) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
